• Utah Medical Products reported 2Q 2026 net income of USD 2.69 million, down 11.9% year over year; diluted EPS fell 10.1% to USD 0.84.
• Revenue dropped 14.3% to USD 8.53 million, reflecting no revenue from PendoTECH or its former China distributor.
• Operating income declined 17.1% to USD 2.65 million, pressured by USD 213,000 higher U.S. litigation costs.
• For 1H 2026, net income decreased 13.1% to USD 5.29 million on a 12.3% revenue slide to USD 17.25 million.
• Management now expects a 10%-13% full-year 2026 revenue decline versus 2025, citing slower-than-expected new biopharma OEM customer sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Utah Medical Products Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607230900ACCESSWRNAPR_____1195225) on July 23, 2026, and is solely responsible for the information contained therein.